person · Reporting owner

Perceptive Xontogeny Venture Fund II, LP

Disclosed activity across 3 companies

Tapewire entity: 70910
SEC CIK: 0001851820

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Landos Biopharma, Inc.LABP · Entity 90644	10% owner	January 10, 2023	January 11, 2023
LeonaBio, Inc.ATHA · Entity 1487	Director · 10% owner	December 23, 2025	December 23, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Landos Biopharma, Inc.

Report date January 10, 2023 · Filed January 11, 2023

Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, Perceptive Xontogeny Venture Fund, LP, EDELMAN JOSEPH

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Pre-funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01	IndirectSee footnote	27,272,727	Reported balance After 2023-01-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-10 · Purchase · Acquired 27,272,727 · Balance 27,272,727 F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Pre-funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01	IndirectSee footnote	3,636,363	Reported balance After 2023-01-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-10 · Purchase · Acquired 3,636,363 · Balance 3,636,363 F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

F3: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

LeonaBio, Inc.

Report date December 23, 2025 · Filed December 23, 2025

Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	1,529,566	Reported balance After 2025-12-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-23 · Grant · Acquired 989,270 · Balance 1,529,566 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	329,756	Reported balance After 2025-12-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-23 · Grant · Acquired 329,756 · Balance 329,756 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F3: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnotes	1,372,935	Reported balance After 2025-12-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-23 · Grant · Acquired 1,372,935 · Balance 1,372,935 F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F4: The Pre-Funded Warrants do not expire. F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnotes	457,645	Reported balance After 2025-12-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-23 · Grant · Acquired 457,645 · Balance 457,645 F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F4: The Pre-Funded Warrants do not expire. F3: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnotes	5,502,402	Reported balance After 2025-12-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-23 · Grant · Acquired 5,502,402 · Balance 5,502,402 F7: The securities were issued to Sermonix Pharmaceuticals, Inc. ("Sermonix") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire. F11: The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Sermonix Beneficial Ownership Limitation"). As of the date hereof, the Sermonix Beneficial Ownership Limitation does not permit Sermonix to exercise any of its Warrants. F8: The securities are directly held by Sermonix. An affiliate of the Advisor currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35	IndirectSee Footnotes	3,838,583	Reported balance After 2025-12-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-23 · Grant · Acquired 3,838,583 · Balance 3,838,583 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F5: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35	IndirectSee Footnotes	1,279,526	Reported balance After 2025-12-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-23 · Grant · Acquired 1,279,526 · Balance 1,279,526 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F5: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F3: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.62	IndirectSee Footnotes	3,543,307	Reported balance After 2025-12-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-23 · Grant · Acquired 3,543,307 · Balance 3,543,307 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F6: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.62	IndirectSee Footnotes	1,181,101	Reported balance After 2025-12-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-23 · Grant · Acquired 1,181,101 · Balance 1,181,101 F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F6: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F3: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant.

F2: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor.

F3: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor.

F4: The Pre-Funded Warrants do not expire.

F5: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030.

F6: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030.

F7: The securities were issued to Sermonix Pharmaceuticals, Inc. ("Sermonix") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire.

F8: The securities are directly held by Sermonix. An affiliate of the Advisor currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix.

F9: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

F10: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants.

F11: The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Sermonix Beneficial Ownership Limitation"). As of the date hereof, the Sermonix Beneficial Ownership Limitation does not permit Sermonix to exercise any of its Warrants.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CARGO Therapeutics, Inc.

Report date November 14, 2023 · Filed November 14, 2023

Jointly reported with PERCEPTIVE ADVISORS LLC, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, EDELMAN JOSEPH

Section 16 reporting ended · disclosed 2023-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,579,502	Reported balance After 2023-11-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-11-14 · Conversion · Acquired 2,579,502 · Balance 2,579,502 F1: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,912,835	Reported balance After 2023-11-14 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-11-14 · Purchase · Acquired 333,333 · Balance 2,912,835 F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	333,333	Reported balance After 2023-11-14 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2023-11-14 · Purchase · Acquired 333,333 · Balance 333,333 F3: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund. F4: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2023-11-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-14 · Conversion · Disposed 2,579,502 · Balance 0 F1: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date.

F2: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor.

F3: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund.

F4: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantPre-Funded Warrant (right to buy) · Derivative	5,502,402	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 9 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 5,502,402 Underlying: Common Stock · 5,502,402 shares Expires not disclosed F7 · price: The securities were issued to Sermonix Pharmaceuticals, Inc. ("Sermonix") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire. F7 · derivative.exercise_date: The securities were issued to Sermonix Pharmaceuticals, Inc. ("Sermonix") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire. F11 · derivative.exercise_date: The terms of the Pre-Funded Warrants provide that such warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Sermonix Beneficial Ownership Limitation"). As of the date hereof, the Sermonix Beneficial Ownership Limitation does not permit Sermonix to exercise any of its Warrants. F7 · derivative.expiration_date: The securities were issued to Sermonix Pharmaceuticals, Inc. ("Sermonix") in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants will become exercisable upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval. The Pre-Funded Warrants do not expire. F8 · ownership.nature: The securities are directly held by Sermonix. An affiliate of the Advisor currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantSeries B Warrant (right to buy) · Derivative	1,181,101	$6.35 Strike: $7.62	$7,499,991.35	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 8 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,181,101 Underlying: Common Stock · 1,181,101 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F6 · derivative.exercise_date: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F6 · derivative.expiration_date: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantSeries A Warrant (right to buy) · Derivative	1,279,526	$6.35 Strike: $6.35	$8,124,990.10	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 7 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,279,526 Underlying: Common Stock · 1,279,526 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F5 · derivative.exercise_date: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F5 · derivative.expiration_date: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantPre-Funded Warrant (right to buy) · Derivative	457,645	$6.35 Strike: $0.00	$2,905,588.11	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 6 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 457,645 Underlying: Common Stock · 457,645 shares Expires not disclosed F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F4 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantSeries B Warrant (right to buy) · Derivative	3,543,307	$6.35 Strike: $7.62	$22,499,999.45	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 5 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 3,543,307 Underlying: Common Stock · 3,543,307 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F6 · derivative.exercise_date: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F6 · derivative.expiration_date: The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. (the "Series B Expiration Date") and expire on the earlier of (1) the 30th day following the Series B Expiration Date and (2) December 23, 2030. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantSeries A Warrant (right to buy) · Derivative	3,838,583	$6.35 Strike: $6.35	$24,375,002.05	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 3,838,583 Underlying: Common Stock · 3,838,583 shares Expires not disclosed F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F5 · derivative.exercise_date: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F5 · derivative.expiration_date: The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026 (the "Series A Expiration Date") and expire on the earlier of (1) the 30th day following the Series A Expiration Date and (2) December 23, 2030. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantPre-Funded Warrant (right to buy) · Derivative	1,372,935	$6.35 Strike: $0.00	$8,716,764.32	Disclosure SEC source: 0001012975-25-000979 · form4.xml · derivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,372,935 Underlying: Common Stock · 1,372,935 shares Expires not disclosed F10 · derivative.exercise_date: The terms of the Pre-Funded Warrants, Series A Warrants and Series B Warrants provide that such warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their Warrants. F4 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantCommon Stock	329,756	$6.35	$2,093,950.60	Disclosure SEC source: 0001012975-25-000979 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 329,756 F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, LP ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by the Advisor, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2025 Filed Dec 23, 2025 22:12 UTC	LeonaBio, Inc. ATHA · Entity 1487	GrantCommon Stock	989,270	$6.35	$6,281,864.50	Disclosure SEC source: 0001012975-25-000979 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 1,529,566 F1 · price: Represents the combined purchase price for each share of Common Stock and accompanying Series A Warrant and Series B Warrant. F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. F9 · ownership.nature: Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
November 14, 2023 Filed Nov 14, 2023 21:32 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionSeries A-1 Convertible Preferred Stock · Derivative	2,579,502	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-020811 · form4.xml · derivative · entry 4 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Former 10% Owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Former 10% Owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Former 10% Owner EDELMAN JOSEPH · CIK 0001164426 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,579,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F1 · price: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F2 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4 · ownership.nature: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
November 14, 2023 Filed Nov 14, 2023 21:32 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	PurchaseCommon Stock	333,333	$15.00	$4,999,995.00	Disclosure SEC source: 0001062993-23-020811 · form4.xml · nonDerivative · entry 3 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Former 10% Owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Former 10% Owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Former 10% Owner EDELMAN JOSEPH · CIK 0001164426 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 333,333 F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund. F4 · ownership.nature: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
November 14, 2023 Filed Nov 14, 2023 21:32 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	PurchaseCommon Stock	333,333	$15.00	$4,999,995.00	Disclosure SEC source: 0001062993-23-020811 · form4.xml · nonDerivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Former 10% Owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Former 10% Owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Former 10% Owner EDELMAN JOSEPH · CIK 0001164426 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,912,835 F2 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4 · ownership.nature: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
November 14, 2023 Filed Nov 14, 2023 21:32 UTC	CARGO Therapeutics, Inc. CRGX · Entity 76319	ConversionCommon Stock	2,579,502	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-020811 · form4.xml · nonDerivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Former 10% Owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Former 10% Owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · Former 10% Owner EDELMAN JOSEPH · CIK 0001164426 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,579,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 convertible preferred stock will automatically convert into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A-1 convertible preferred stock has no expiration date. F2 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment manager of PXV II and is controlled by Perceptive Advisors LLC (the "Advisor"), and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. F4 · ownership.nature: The Venture Advisor, the Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
January 10, 2023 Filed Jan 11, 2023 23:45 UTC	Landos Biopharma, Inc. LABP · Entity 90644	PurchasePre-funded Warrant · Derivative	3,636,363	$0.54 Strike: $0.01	$1,963,636.02	Disclosure SEC source: 0001062993-23-000853 · form4.xml · derivative · entry 2 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,636,363 Underlying: Common Stock · 3,636,363 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
January 10, 2023 Filed Jan 11, 2023 23:45 UTC	Landos Biopharma, Inc. LABP · Entity 90644	PurchasePre-funded Warrant · Derivative	27,272,727	$0.54 Strike: $0.01	$14,727,272.58	Disclosure SEC source: 0001062993-23-000853 · form4.xml · derivative · entry 1 PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner Perceptive Xontogeny Venture Fund II, LP · CIK 0001851820 · 10% owner EDELMAN JOSEPH · CIK 0001164426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,272,727 Underlying: Common Stock · 27,272,727 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.